RGNXRegenxbio Inc

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting...

RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.

The U.S. Food and Drug Administration has agreed to reconsider Regenxbio’s application for its experimental gene therapy Navsunli.

Stocks Drift As Chips Extend Gains, Oil Slides On Positive US-Iran Talks Futures are modestly lower coming off the US holiday weekend, after equities finished higher last week with both Dow and Russell clocking new ATHs and SPX finishing in the green for the 11th time in the last 12...

REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS...

Investors need to pay close attention to RGNX stock based on the movements in the options market lately.

OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.

Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach.

Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway...